Hybrid peptide containing RGDF (Arg-Gly-Asp-Phe) coupled with the carboxy terminal part of alpha 2-antiplasmin capable of inhibiting platelet aggregation and promoting fibrinolysis
- PMID: 7795148
- DOI: 10.1097/00001721-199502000-00002
Hybrid peptide containing RGDF (Arg-Gly-Asp-Phe) coupled with the carboxy terminal part of alpha 2-antiplasmin capable of inhibiting platelet aggregation and promoting fibrinolysis
Abstract
The aim of this study was to synthesize and investigate hybrid peptides which contain the RGD (Arg-Gly-Asp) sequence coupled with lysine residues in special arrangements (antiplasmin carboxyterminal peptide) in an effort to simultaneously inhibit platelet aggregation and promote fibrinolysis. The in vitro haemostatic modifying properties of the synthesized peptides were tested by ADP-induced platelet aggregation, plasmin-generation tests and fibrin-clot lysis assays. The hybrid peptide RGDFAP, composed of RGDF (Arg-Gly-Asp-Phe) coupled to a synthetic peptide residue of the carboxyterminal part of antiplasmin (AP26) inhibited platelet activation and increased plasmin generation and in vitro fibrin-clot lysis.
Similar articles
-
[A new thrombocyte aggregation-inhibiting and fibrinolysis-promoting synthetic molecule: RGDF (Arg-Gly-Asp-Phe) coupled with the carboxyterminal antiplasmin peptide].Orv Hetil. 1995 Jan 15;136(3):129-33. Orv Hetil. 1995. PMID: 7870410 Review. Hungarian.
-
RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets.Blood Coagul Fibrinolysis. 1995 Jul;6(5):481-5. Blood Coagul Fibrinolysis. 1995. PMID: 8589217
-
Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.Thromb Res. 2002 Feb 1;105(3):263-70. doi: 10.1016/s0049-3848(02)00030-0. Thromb Res. 2002. PMID: 11927133
-
Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.J Pharmacol Exp Ther. 1991 Dec;259(3):1371-8. J Pharmacol Exp Ther. 1991. PMID: 1762085
-
New pentamidine related substances which simultaneously inhibit platelet aggregation and accelerate plasmin generation and in vitro clot lysis.Blood Coagul Fibrinolysis. 1996 Mar;7(2):256-8. doi: 10.1097/00001721-199603000-00037. Blood Coagul Fibrinolysis. 1996. PMID: 8735833
Cited by
-
Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.Int J Mol Sci. 2021 Nov 21;22(22):12537. doi: 10.3390/ijms222212537. Int J Mol Sci. 2021. PMID: 34830419 Free PMC article. Review.
-
Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.Cardiovasc Diabetol. 2017 Mar 9;16(1):34. doi: 10.1186/s12933-017-0515-9. Cardiovasc Diabetol. 2017. PMID: 28279217 Free PMC article. Review.
-
α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis.Life (Basel). 2022 Mar 9;12(3):396. doi: 10.3390/life12030396. Life (Basel). 2022. PMID: 35330147 Free PMC article. Review.
-
Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target.TH Open. 2022 Nov 18;6(4):e396-e407. doi: 10.1055/a-1957-6817. eCollection 2022 Oct. TH Open. 2022. PMID: 36452200 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical